Gentium Announces Resignation of Board Member
March 28, 2013 21:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, March 28, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that Dr. Glenn Cooper has resigned from the Company's Board of Directors,...
Gentium Reports Fourth Quarter and Year End 2012 Financial Results
March 28, 2013 07:23 ET
|
Gentium S.p.A.
Total product sales of EUR 27.63 million (US$ 36.43 million) exceeding Company's product sales guidance of EUR 22-25 million (US$ 29-33 million)
Defibrotide uptake increased by 35% with sales...
Gentium Announces Initiation of Phase 1 study in Japan
March 26, 2013 08:35 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, March 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today has announced that the medical team from the National University Corporation...
Gentium Receives Negative Opinion From the CHMP on Defibrotide for the Treatment and Prevention of VOD
March 22, 2013 08:30 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, March 22, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been informed by the European Medicines Agency's ("EMA") Committee for...
Gentium to Report Fourth Quarter and Full Year 2012 Financial Results
March 21, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, March 21, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced today that it will report its fourth quarter and full year 2012 financial results on Thursday,...
Gentium Provides Update on the Review of Defibrotide Marketing Authorization
February 21, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, the Company had presented an oral explanation at the European Medicines...
Gentium Provides an Update on Defibrotide MAA to EMA
January 17, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been informed that the Company's Marketing Authorization Application...
Gentium Submit 2nd LoOIs Response to the EMA's CHMP for Defibrotide MAA
December 18, 2012 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Dec. 18, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has submitted responses to the second List of Outstanding Issues ("LoOIs")...
Results From Gentium's Treatment IND for Defibrotide Presented at the American Society of Hematology Annual Meeting
December 13, 2012 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that additional data from ongoing trials of Defibrotide were presented this...
Data From Non HSCT VOD Patients Treated With Defibrotide and a Treatment IND Update to be Presented at the American Society of Hematology Annual Meeting
December 07, 2012 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that an oral presentation and poster abstracts on Defibrotide will be...